VEGF-A121 Increases After Bevacizumab Treatment in Colorectal Cancer Patients
Author Information
Author(s): Okawa Masashi, Yamakuchi Munekazu, Bibek Aryal, Takenouchi Kazunori, Maywar Drew N., Yamada Shingo, Inoue Keiichi, Higurashi Kazuhiko, Nakazawa Junichi, Kawahira Masahiro, Kodama Tomoko, Tanoue Kiyonori, Oyama Yoko, Higashi Sadayuki, Fujisaki Chieko, Hashinokuchi Hirohito, Tabaru Akito, Kanda Hideaki, Tachioka Shuji, Imoto Yutaka, Hashiguchi Teruto, Soga Yoshiharu
Primary Institution: Kagoshima University
Hypothesis
Can VEGF-A121 and VEGF-A165 be distinguished as biomarkers in cancer patients undergoing bevacizumab treatment?
Conclusion
VEGF-A121 is a clear marker of bevacizumab therapy, while VEGF-A165 does not show significant changes.
Supporting Evidence
- VEGF-A121 levels increased significantly in both serum and plasma after treatment.
- VEGF-A165 levels decreased in serum post-treatment.
- Statistical analysis showed significant changes in VEGF-A121 concentrations.
- Immunoprecipitation studies confirmed the presence of VEGF-A121 in the serum.
- Patients were first-time recipients of bevacizumab.
- Blood samples were collected at multiple time points for accurate measurement.
- VEGF-A121 is suggested as a potential biomarker for monitoring treatment response.
- Further research is needed to validate these findings in larger cohorts.
Takeaway
This study found that a specific protein, VEGF-A121, goes up in cancer patients after they receive a treatment called bevacizumab, which might help doctors track how well the treatment is working.
Methodology
An ELISA was used to measure VEGF-A121 and VEGF-A165 levels in blood samples from patients before and after bevacizumab treatment.
Potential Biases
Potential bias due to the observational nature of the study and lack of randomization.
Limitations
The study had a small sample size and lacked a control group of untreated patients.
Participant Demographics
Patients with advanced colorectal cancer, including both males and females aged 33 to 75.
Statistical Information
P-Value
0.0024
Confidence Interval
[468.5, 1128.9]
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website